TrialClinical journal of the American Society of Nephrology : CJASN2026

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial.

Jennifer Yee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.